Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06694857 · ClinicalTrials.gov registry record · Phase 4
A Prospective Evaluation of the Filler for Jaw Contouring
A Phase 4 study of Dermal Fillers, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT06694857: Completed Phase 4 study of Dermal Fillers, sponsored by University of Pennsylvania.
NCT06694857 is a Phase 4 study of Dermal Fillers that has completed, run by University of Pennsylvania. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06694857, a Phase 4 study of Dermal Fillers, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this prospective study is to analyze volumetric changes in the lower face after hyaluronic acid filler injections over 90 days. The main question it aims to answer is: To quantify volume change of the lower face area over time after injection of filler * Participants will receive hyaluronic acid filler injections (Juvéderm Volux XC) for contouring of the jawline. Each patient will receive FDA approved dosages of filler to the lower face region to treat facial contour or asymmetry, as per FDA approved indications. * Prior to injection patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging.
Primary Outcome
3D- images will be collected to determine change in volume following from pre-intervention to post-intervention (30 days)
Conditions Studied
Interventions
- DRUG HA filler
Study Locations (1)
Pennsylvania
- Penn Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2025-11-01 |
| Phase | Phase 4 |
What the finished NCT06694857 record still lists
NCT06694857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Dermal Fillers appearing as the primary indexed condition, and to 1 intervention - of which HA filler is the first listed.
NCT06694857 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06694857 about?
NCT06694857 is a clinical study titled "A Prospective Evaluation of the Filler for Jaw Contouring". The goal of this prospective study is to analyze volumetric changes in the lower face after hyaluronic acid filler injections over 90 days. The main question it aims to answer is: To quantify volume change of the lower face area over time after injection of filler * Participants will receive hyalu...
What is the current status of trial NCT06694857?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2024-10-31. Estimated completion is 2025-11-01.
What conditions does trial NCT06694857 study?
This clinical trial studies the following conditions: Dermal Fillers.
What interventions are being tested in trial NCT06694857?
The interventions under investigation include: HA filler (DRUG).
Who is sponsoring clinical trial NCT06694857?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06694857 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06694857's enrollment target sits among peer trials
14 1902nd of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy